Quantzig Releases Their Guide to Marketing Mix Modeling, Completes Studies for Telecom, BFSI, and Pharma Industries

LONDON–(BUSINESS WIRE)–#BigData–Market mix modeling (MMM) is gaining popularity because of its ability
to forecast future outcomes
based on past performance and
present trends. Marketing mix modeling includes the four ‘P’s: Product,
Price, Promotion and Place, and is used as a tool by analysts for fixing
prices and formulating prudent managerial decisions.

In their recent blog titled ‘Everything
You Need to Know About Marketing Mix Modeling
’, global analytics
and advisory firm Quantzig
evaluates some of the ways companies are using MMM to formulate prudent
managerial decisions and drive profit.

According to Quantzig, “By incorporating MMM, marketers can analyze past
data and present trends, determining its impact on individual marketing
campaigns across different channels. This will in-turn help in making
proper decisions related to budget planning, fund allocation, and
keeping an eye on performance.”

The three stages of the MMM approach are:

  • The pre-planning stage includes analysis of historical data such as
    sales, trends, past campaigns and its drivers.
  • The planning stage is all about forecasting and estimating the
    marketing effectiveness and ROI of marketing activities occurs.
  • The final stage includes tracking of the effectiveness of all
    marketing variables, simulating spends scenarios and re-working the
    marketing activities, based on requirement.

For more insights, get
in touch
with Quantzig’s analytics solutions experts

The MMM technique finds its application in several industries, including
retail and consumer packaged goods (CPG), food and beverage,
telecommunications and IT, and the healthcare industry.

“For the retail and CPG industry, the marketing mix modeling helps to
improve ROI across different marketing channels, optimize expenditure by
eliminating inefficiencies, drive sales by setting better trade
promotions and devise effective pricing strategy,” says Quantzig.
“Applying MMM techniques in the food and beverage industry can identify
the impact of competitive advertising, determine the factors that create
halo effect and help prevent cannibalization.”

Read more: https://www.quantzig.com/blog/everything-need-know-marketing-mix-modeling

Quantzig Marketing Mix Modeling Studies

Quantzig has over 12 years helping leading organizations and leading
firms from across the globe with end-to-end data modeling capabilities
to leverage analytics for prudent decision making. Here are the latest
MMM research studies from Quantzig:

Marketing Mix Models Increase Marketing ROI for Telecom Company

Marketing Mix Optimization for the BFSI Industry

Quantzig Provides Marketing Mix Modeling for the Pharma Industry

About Quantzig

Quantzig is a global analytics and advisory firm with offices in the US,
UK, Canada, China, and India. For more than 12 years, we have assisted
our clients across the globe with end-to-end data modeling capabilities
to leverage analytics for prudent decision making. Today, our firm
consists of 120+ clients, including 45 Fortune 500 companies. For more
information on all of Quantzig’s services and the solutions they have
provided to Fortune 500 clients across all industries, please contact


Jesse Maida
Media & Marketing Executive

Two-Day Course – Preparing for and Managing Successful FDA Inspections (Boston, United States – July 13-14, 2017) – Research and Markets

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Preparing
for and Managing Successful FDA Inspections”
conference to
their offering.

This is a practical, hands-on course designed to provide pharmaceutical,
biopharmaceutical, biologics and medical device professionals with the
information and tools they require to prepare for and manage an FDA
inspection efficiently, effectively and successfully. Many regulated
companies preparing for FDA inspections are not prepared and the outcome
can be negative as we see all the time with enforcement actions.

This seminar provides the fundamentals and the ground rules on how to
prepare for and survive an FDA inspection no matter if you are a Class
I, II, III device or a pharmaceutical or biologics manufacturer. This
presentation will review and emphasize the dos and don’ts and cardinal
rules as to interviewing, how to respond, reviewing documentation,
etiquette, use of certain words, body language, responding to
questions/requests, etc., and certainly replying to 483s and Warning

The course will go through what typically goes on during an FDA
inspection and will then cover how to prepare for, host and follow up to
a regulatory inspection. It will emphasize and focus on the critical and
vital elements that you should do or not do during the inspection.
Typically, FDA inspections can be highly structured and there are
procedures that are to be followed as you prepare for state of
readiness. It is important for anyone who might be involved in the
inspection to be aware of these procedures, including all employees and
personnel to ensure there are no surprises.

The course will also provide information for inspections conducted by
international agencies as well as non-FDA agencies, including
self-inspections for manufacturing and the famous FDA Mock Inspection or
Mock Audit. It will explain how to prepare for an inspection, how to
handle a scheduled or non-scheduled inspection, what to expect during an
inspection and what follow-up to expect after an inspection.

Areas Covered:

– FDA’s Inspectional Authority and History

– FDA Inspection Program Overview

– Key factors for a successful FDA inspection

– Quality System Readiness

– Organization Readiness

– Manage Inspection Outcomes

– Information and Documentation

– How a firm should prepare for an FDA inspection?

– Ways to train employees in view of the inspection

– How to ensure that required documentation is in place

– How to interact with the investigator-DOs and DON’Ts

– What companies should do when the inspection ends

– How to reply to 483s and warning letters

For more information about this conference visit https://www.researchandmarkets.com/research/lj8z2n/preparing_for_and.


Research and Markets
Laura Wood, Senior Manager
EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Topics: Pharmaceutical

Acelity Strengthens Global Commercial Leadership; Names Ramesh Subrahmanian President for International Region

John McAuley appointed as Senior Vice President for Europe as
company increases focus on markets beyond the United States

SAN ANTONIO–(BUSINESS WIRE)–Acelity L.P. Inc., a leading global advanced wound care company, today
announced Ramesh Subrahmanian will join the company as President for the
International region and member of the senior leadership team effective
July 17th. Acelity recently appointed John McAuley as Senior Vice
President for Europe.

Subrahmanian brings more than 25 years of leadership experience in
business development, finance and commercial management from an array of
global pharmaceutical and medical device companies. He is the former
Group President, International for Stryker Corporation where he was
responsible for that company’s commercial markets outside the U.S.
Previously, he served as President, Asia Pacific for Merck & Co., as
well as a range of commercial leadership roles at Sanofi.

“Markets across Asia Pacific, Europe and The Middle East represent
tremendous potential not only to expand and grow our business, but to
deliver our products and therapies to millions of patients in these
areas who would benefit from our portfolio of healing solutions,” said
R. Andrew Eckert, President and CEO of Acelity. “Ramesh brings to
Acelity a diverse and wide-ranging set of capabilities that will
accelerate our global expansion plans. Together with John’s leadership
in Europe, we are now well positioned to execute on our strategy of
geographic expansion and truly deliver our therapies to people across
the globe.”

Subrahmanian holds a professional certification from the Institute of
Chartered Accountants in England & Wales, as well as a degree from the
City of London Polytechnic in Finance and Accounting and a Bachelor of
Commerce, Economics, Financial Management and Accounting from the
University of Bombay in India.

John McAuley is a strong commercial leader and a skilled change agent
with more than 30 years of experience in the medical industry. Most
recently, he served as President of Provider Solutions at TriZetto,
where he led optimization efforts to improve operations and customer
experience. Previously, McAuley served as a Vice President and General
Manager for ADAC Labs where he was a member of the team that earned the
1996 Malcolm Baldrige National Quality Award.

About Acelity

Acelity L.P. Inc. and its subsidiaries are a global advanced wound care
company that leverages the strengths of Kinetic Concepts, Inc. and
Systagenix Wound Management, Limited. Available in more than 90
countries, the innovative and complementary ACELITY™ product portfolio
delivers value through solutions that speed healing and lead the
industry in quality, safety and customer experience. Headquartered in
San Antonio, Texas, Acelity employs nearly 5,000 people around the world.


Cheston Turbyfill, +1-210-515-7757
Moore, +1-210-255-6433
Investor Relations

Viscosupplementation – North America Analysis and Market Forecasts, 2023 – Research and Markets

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “MediPoint:
Viscosupplementation – North America Analysis and Market Forecasts”

report to their offering.

This report analyzes and discusses the major drivers and barriers of
viscosupplementation adoption, and provides an in-depth understanding of
the future outlook for this market by geography, with an overall
emphasis on the current and future trends in the three countries.

North American viscosupplementation market was estimated at $889.4M in
2016 across the three markets (Canada, Mexico, and US). By the end of
the forecast period in 2023, it is estimated that the market will grow
to approximately $1.4B at a Compound Annual Growth Rate (CAGR) of 6.4%.

Osteoarthritis (OA) constitutes a growing public health burden, and is
the most common cause of musculoskeletal disability around the world.
Resulting from a complex interaction of biomechanical, biochemical, and
genetic factors, OA develops slowly and is characterized by the
degradation of the affected joint’s cartilage and bone hypertrophy. The
disability is accompanied by joint pain, stiffness, and loss of range of
motion. Initially treated with various therapies including physical
therapy and nonsteroidal anti-inflammatory drugs (NSAIDs), advanced
cases of OA have traditionally been treated surgically.

However, intra-articular viscosupplementation with hyaluronic acid (HA),
a high-molecular-weight glycosaminoglycan, has become an increasingly
accepted therapeutic alternative to knee replacement surgery in the
symptomatic management of OA over the past decade.

The US represented the largest portion of the market in 2016, holding
95.7% of the regional revenue, and is expected to maintain this
dominance through the forecast period. The US is also expected to be the
fastest-growing market through 2023, at a CAGR of 6.4%, while the
slowest growth will be observed in Mexico.

Key drivers of the viscosupplementation market in the forecast period

  • The rising prevalence of osteoarthritis (OA) due to increasing aging
    and obese populations.
  • The evolving multimodal treatment paradigm for OA.
  • Patients seeking to delay knee replacement surgery in an effort to
    maintain an active lifestyle.

Key Topics Covered:

1 About the Authors

2 Table of Contents

3 Executive Summary

4 Introduction

5 Market Outlook

6 Market Insights

7 Competitive Assessment

8 Appendix

Companies Mentioned

– Anika Therapeutics

– Ferring Pharmaceuticals

– Fidia Farmaceutici

– Sanofi

– Seikagaku Corporation

For more information about this report visit https://www.researchandmarkets.com/research/mlnv5d/medipoint


Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Topics: Orthopedic

Calyxt Files Registration Statement for Proposed Initial Public Offering

ST. PAUL, Minn. & NEW YORK–(BUSINESS WIRE)–Regulatory News:

Cellectis S.A. (Alternext : ALCLS ; Nasdaq : CLLS) and Calyxt, Inc.
announced that Calyxt has publicly filed a registration statement on
Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating
to a proposed initial public offering (IPO) of shares of Calyxt common
stock. Calyxt is Cellectis’ 100% owned gene editing agriculture company.
The number of shares to be offered and the price range for the offering
have not yet been determined, although Cellectis intends to retain
majority ownership of Calyxt.

Citigroup, Credit Suisse and Jefferies are acting as joint book-running
managers for the proposed offering. Wells Fargo Securities is acting as
lead manager and Ladenburg Thalmann is acting as co-manager.

This offering will be made only by means of a prospectus (included in
the registration statement on Form S-1). When available, a copy of the
preliminary prospectus may be obtained from Citigroup Global Markets
Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, or by telephone at (800) 831-9146; Credit Suisse
Securities (USA) LLC, Attention: Prospectus Department, One Madison
Avenue, New York, NY 10010, or by telephone at (800) 221-1037, or by
email at newyork.prospectus@credit-suisse.com;
or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520
Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877)
547-6340, or by e-mail at Prospectus_Department@Jefferies.com.

A registration statement relating to these securities has been filed
with the SEC but has not yet become effective. The registration
statement is available at https://www.cellectis.com/FINAL.calyxt.s1.june.23.2017.pdf.
These securities may not be sold, nor may offers to buy be accepted,
prior to the time the registration statement becomes effective. This
press release shall not constitute an offer to sell or the solicitation
of an offer to buy these securities, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or

This press release contains inside information within the meaning of
Article 7(1) of the EU Market Abuse Regulation.


Jennifer Moore, VP Communications
email: media@calyxt.com
/ media@cellectis.com
Kasunich / Nick Opich
KCSA Strategic Communications
212-896-1241 / 212-896-1206
email: ckasunich@kcsa.com

Simon Harnest, VP Corporate Strategy and Finance
email: simon.harnest@cellectis.com

NeuroMetrix Provides Update on Quell Wearable Pain Relief Clinical Program

WALTHAM, Mass.–(BUSINESS WIRE)–$NURO #NeuroMetrix–NeuroMetrix, Inc. (Nasdaq: NURO) today provided an update on its Quell®
clinical program. Quell is a wearable non-invasive neurostimulator that
provides widespread analgesia for chronic pain. In addition to delivery
of therapy, the device and its associated smartphone app track
utilization and health metrics including pain, sleep, activity and gait.

The objective of the clinical program is to build clinical credibility
for Quell technology, further scientific understanding of its mechanism
of action, and better identify Quell therapy responders. In a study
published last year in the Journal
of Pain Research
, 81% of subjects reported a general improvement in
their chronic pain and 67% reported a reduction in pain medication use
after 60 days of use. Additional study findings included decreased pain
interference with sleep and walking ability. There are currently 4
studies underway.

  • Quell TENS band for Chemotherapy-Induced
    Peripheral Neuropathy (CIPN). A Feasibility Study. University of
    Rochester Medical Center, University of Rochester, Rochester, NY.

    open label study is evaluating Quell efficacy, assessed by pain relief
    and continued device use, in subjects with CIPN. Preliminary results
    were presented at the recent American Pain Society meeting May 17-20
    in Pittsburgh, PA. Among subjects completing the first 6 weeks of the
    study, 73% decided to continue using their Quell device. In addition,
    statistically significant reductions in pain, tingling, cramping and
    numbness were observed.
  • Quell Opioid Reduction and Pain Relief in
    Patients with Cancer. Scripps Translational Science Institute, Scripps
    Health, San Diego, CA.

    This randomized sham-controlled
    study is evaluating opioid use reduction in patients with various
    forms of cancer pain. The study is fully enrolled. Preliminary results
    are expected in Q4 ’17.
  • Efficacy of the Quell Wearable Device for
    Chronic Low Back Pain. Brigham and Women’s Hospital, Harvard Medical
    School, Boston, MA.

    This randomized controlled study is
    evaluating pain relief and quality of life improvements in subjects
    with low back pain using Quell compared to control subjects on
    standard therapy. The study is 75% enrolled. Preliminary results are
    expected in Q4 ’17.
  • Prospective Validation of Quell Sleep/Wake
    Classification and Periodic Leg Movement Detection. Massachusetts
    General Hospital, Harvard Medical School, Boston, MA.

    study is comparing Quell sleep tracking to gold standard
    polysomnography. The study is 25% enrolled. Preliminary results are
    expected in Q4 ’17.

“We believe that the conduct of clinical studies evaluating various
aspects of Quell technology is essential to continued evolution of the
platform for both treatment of chronic pain and development of
additional indications,” said Shai N. Gozani, M.D., Ph.D., President and
CEO of NeuroMetrix. “We are honored to work with outstanding academic
medical centers in this effort, and look forward to learning from these
initial studies and expanding our clinical program in the near future.”

About Quell

Quell is designed for millions of people suffering from chronic pain.
The advanced wearable device is lightweight and can be worn during the
day while active, and at night while sleeping. It has been cleared by
the FDA for treatment of chronic pain without a prescription. In a
recent study, 81% of Quell users reported an improvement in their
chronic pain. Quell users can personalize and manage therapy discreetly
via the Quell Relief app. Quell also offers advanced health tracking
relevant to chronic pain sufferers including pain, sleep, activity, and
gait. Quell was the winner of the 2016 SXSW (South by Southwest)
Innovation Award for Best Wearable Technology. Quell is available at
select healthcare professionals and retailers. Visit QuellRelief.com for
more information.

About NeuroMetrix

NeuroMetrix is a commercial stage, innovation driven healthcare company
combining bioelectrical and digital medicine to address chronic health
conditions including chronic pain, sleep disorders, and diabetes. The
company’s lead product is Quell, an over-the-counter wearable
therapeutic device for chronic pain. Quell is integrated into a digital
health platform that helps patients optimize their therapy and decrease
the impact of chronic pain on their quality of life. The company also
markets DPNCheck®, a rapid point-of-care test for diabetic
neuropathy, which is the most common long-term complication of Type 2
diabetes. The company maintains an active research effort and has
several pipeline programs. The company is located in Waltham,
Massachusetts and was founded as a spinoff from the Harvard-MIT Division
of Health Sciences and Technology in 1996. For more information, please
visit NeuroMetrix.com.


NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer

Viscosupplementation Analysis and Market Forecasts, 2023 – Research and Markets

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “MediPoint:
Viscosupplementation – Global Analysis and Market Forecasts”

report to their offering.

Global viscosupplementation market was estimated at $2.1B in 2016
spanning 39 markets. By the end of the forecast period in 2023, it is
estimated that the market will grow to approximately $3.1B at a Compound
Annual Growth Rate (CAGR) of 6.0%.

South America viscosupplementation market is projected to grow at a CAGR
of 6.7% during the forecast period, followed by North America, APAC,
Middle East and Africa at a CAGR of 6.4%, 6.3% and 5.0% respectively.
The European viscosupplementation market is projected to grow at a CAGR
of 3.5% during the forecast period. The US represented the largest
portion of the market in 2016, holding 95.7% of the regional revenue,
and is expected to maintain this dominance through the forecast period.

The market for viscosupplementation is highly fragmented, with key
players varying by region and country. Unlike most orthopedic device
markets, the market for viscosupplementation is largely populated by
pharmaceutical companies. Although many companies maintain a direct
presence in the markets they sell to, some have coordinated marketing
and distribution partnerships with major orthopedic players in an effort
to leverage geographical experience and existing relationships with
orthopedic surgeons.

Key drivers of the viscosupplementation market are:

  • The rising prevalence of osteoarthritis (OA) due to increasing aging
    and obese populations.
  • The evolving multimodal treatment paradigm for OA.
  • Patients seeking to delay knee replacement surgery in an effort to
    maintain an active lifestyle.

Companies mentioned in this report:

  • Anika Therapeutics
  • Ferring Pharmaceuticals
  • Fidia Farmaceutici
  • Sanofi
  • Seikagaku Corporation

Key Topics Covered:

1 About the Authors

2 Table of Contents

3 Executive Summary

4 Introduction

5 Market Outlook

6 Market Insights

7 Competitive Assessment

8 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/slc7wq/medipoint


Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Topics: Orthopedic

iBIO Institute EDUCATE Center Keeps Local Youth Exploring This Summer Through STEMGirls Summer Camp

125 Girls Set to Participate in Industry-focused STEM Summer Camps

WAUKEGAN, Ill.–(BUSINESS WIRE)–125 girls have registered for the second annual STEMGirls Summer Camp
hosted by the iBIO Institute’s EDUCATE Center in partnership with
Waukegan to College and Andrew Cooke Magnet Elementary School. The
Summer Camp, held in Waukegan, will enhance summer STEM exploration for
the 3rd-8th grade participants.

Camp programming consists of fun hands-on activities, sessions with STEM
professionals and field trips. The Summer Camp is made possible through
generous support by Abbott (North Chicago, IL) the Astellas USA
Foundation (Northbrook, IL), Horizon Pharma (Lake Forest, IL) and the
VWR Foundation.

Camp activities will focus on how STEM techniques are used in Chemical,
Mechanical and Medical Engineering including:

  • Exploding Baggies, Bubbling Balloons, Iodine Clocks, Film Canister
    Rockets: Exploring how concentration, temperature, agitation and
    surface area affect the way a reaction happens.
  • Juice Box Motor Boats: Design and competition
  • 3-D Printing: From Design to Product
  • Heart Health: Making Stethoscopes
  • Demonstrations of cardiac catheters, stents, and heart valve models
  • Fire Flies or Bust: Bioluminescence and making our own chemical glow
    and decoding female firefly flash responses
  • Coding: Create a Binary Bracelet, Mouse Maze, Algorithm Origami

“Our mission is to provide high-quality programming that helps spark
interest in STEM,” says iBIO Institute Executive Vice President, John
Conrad. “Third to eighth grade is a critical time where many girls
decide whether STEM is for them. The STEMGirls Summer Camp promotes STEM
and STEM careers in a way that inspires girls to begin planning a future
in the STEM industries.”

“Abbott employee volunteers are looking forward to sharing their
expertise and passion for science and engineering at the iBIO STEMGirls
summer camp,” said John Frels, vice president of research and
development for Abbott’s diagnostics business. “This year, the girls
will have a chance to explore cutting edge technologies such as 3-D
printing, and learn about the science of bioluminescence. Through
hands-on experiences that are interactive and fun, we can help bring
science and engineering to life – and we hope that these experiences
will inspire the girls to consider pursuing careers in science and
engineering in the future.”

“The STEMGirls program offers girls a unique opportunity to be
challenged and inspired by STEM activities working closely with Astellas
volunteers,” said Moyra Knight, president of Astellas USA Foundation.
“Astellas USA Foundation is proud to help support the STEMGirls Summer
Camp as part of our Science WoRx program to encourage more girls to
pursue STEM careers.”

Anyone is welcome to register and attend Family Day on the last day of
camp, June 23, 2017, from 11 a.m. to 2 p.m. At Family Day, parents and
siblings join the girls for a fun and informative day. Campers will host
a STEM fair to show what they have learned during their week. Lunch will
be served.

Camp Details:
STEMGirls Summer Camp
June 19-23, 2017
from 9:00 AM to 3:00 PM
522 Belvidere Street
Waukegan, IL 60085

Family Day Details:
June 23, 2016 from 11:00 AM to 2:00 PM.
register please email mnaleway@ibio.org.
or register here: www.goo.gl/fX8Atp

About iBIO Institute EDUCATE Center

The iBIO Institute is a 501(c)(3) non-profit that focuses on
orchestrating business leadership in delivery of world-class,
educational programs and job-creating new technology ventures. The
Institute’s EDUCATE Center delivers industry-led science and math
programs for teachers and students, thereby inspiring the next
generation of innovators and helping restore America’s leadership in
technology education. EDUCATE’s hands-on, inquiry-based STEM programs
have impacted over 1000 teachers and 90,000 Illinois students since 2003.


iBIO Institute
John Conrad, 312-422-1111

Biopharmaceutical Contract Manufacturing Market (2nd Edition), 2017-2027 – Research and Markets

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Biopharmaceutical
Contract Manufacturing Market (2nd Edition), 2017-2027”
to their offering.

Over the years, the biopharmaceutical market has grown into a prominent
and promising segment of the overall pharmaceutical industry.
Characterized by a number of blockbuster therapies (HUMIRA®, RITUXAN®,
Lantus®, Avastin®, Herceptin® and REMICADE®) and a robust pipeline of
product therapy candidates, the market is poised for significant growth
in the coming years.

It is worth mentioning that much of the anticipated success of the
biopharmaceutical market is dependent on new biologics, which are
currently under development, and biosimilars, which are generic versions
of these biologics. The field continues to witness significant growth in
terms of innovation; this activity is clearly indicative of the growing
demand for biologics to cater to existing unmet needs in the industry.

It is necessary to highlight the fact that the development and
manufacturing processes for biologics are complex, and usually require
advanced capabilities and specialized expertise. In addition, the costs
associated with acquiring capabilities in this field are exorbitant and,
therefore, it is difficult for companies with limited finances and
capacity constraints to succeed by themselves. These complications have
led many stakeholders in the biopharmaceutical industry to outsource
significant parts of their business operations to contract service

As a result of the above mentioned industry dynamics, the contract
manufacturing industry landscape is steadily evolving. CMOs aiming to
consolidate their presence in the market are rapidly expanding their
service portfolios to provide end-to-end services to their clients and

Companies Mentioned

  • 3P Biopharmaceuticals
  • Aalto Scientific
  • AbbVie Contract Manufacturing
  • AbGenomics
  • Ablynx
  • Abzena
  • ACES Pharma
  • Acticor Biotech
  • Active Biotech
  • Adar Biotech
  • ADC Therapeutics
  • Adimab
  • Advanced BioScience Laboratories (ABL)
  • Advanced Biotherapeutics Consulting (ABC)
  • Affimed
  • Affinity Life Sciences
  • Agensys
  • Ajinomoto Althea
  • Albany Molecular Research (AMRI)
  • Alberta Cell Therapy Manufacturing
  • (400+ Others)

Key Topics Covered:
















For more information about this report visit https://www.researchandmarkets.com/research/zsq23q/biopharmaceutical


Research and Markets
Laura Wood, Senior Manager
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Topics: Biopharmaceuticals

Kadmon to Present Interim Data on KD025 in Chronic Graft-Versus-Host Disease (cGVHD) at R&D Day

— Event on July 11 in New York City with Live Webcast —

NEW YORK–(BUSINESS WIRE)–Kadmon Holdings, Inc. (NYSE: KDMN) (“Kadmon” or the “Company”) will
present interim data from its ongoing Phase 2 clinical trial of KD025,
the Company’s lead ROCK2 inhibitor, in previously treated patients with
chronic graft-versus-host disease (“cGVHD”). The data will be presented
at Kadmon’s Research and Development (“R&D”) Day in New York City on
Tuesday, July 11, 2017, from 8:45 a.m. to 11:00 a.m. ET.

The R&D Day will feature presentations by key opinion leaders, including
Bruce Blazar, M.D., Regents Professor in the Department of Pediatrics,
Chief of the Pediatric Blood and Marrow Transplantation Program and Vice
Dean for Clinical Investigation at the School of Medicine at the
University of Minnesota, Minneapolis, MN. Dr. Blazar will share the
findings of his preclinical research on KD025 in cGVHD. Also presenting
is Amandeep Salhotra, M.D., Assistant Professor, Hematology and
Hematopoietic Cell Transplantation at City of Hope, Duarte, CA. Dr.
Salhotra will present interim data from the first cohort (KD025 200 mg
QD) of the ongoing cGVHD trial.

Kadmon’s executive management team, led by Harlan W. Waksal, M.D.,
President and Chief Executive Officer, will provide an update on KD025
as well as the Company’s ROCK inhibitor platform. KD025 is being studied
in three ongoing clinical trials in autoimmune and fibrotic diseases: A
placebo-controlled Phase 2 clinical trial in moderate to severe
psoriasis, an open-label Phase 2 clinical trial in idiopathic pulmonary
fibrosis and an open-label Phase 2 clinical trial in cGVHD.

The R&D Day is intended for institutional investors and sell-side
analysts only. For more information, please email Ellen Tremaine,
Manager, Investor Relations at Kadmon, at ellen.tremaine@kadmon.com.
A live and archived webcast of the event, with slides, will be available
on the Investors section of the Kadmon website at www.kadmon.com.

About Kadmon Holdings, Inc.

Kadmon Holdings, Inc. is a fully integrated biopharmaceutical company
focused on developing innovative products for significant unmet medical
needs. We have a diversified product pipeline in autoimmune and fibrotic
diseases, oncology and genetic diseases.

Safe Harbor Statement

This press release contains forward-looking statements. Such statements
may be preceded by the words “may,” “will,” “should,” “expects,”
“plans,” “anticipates,” “could,” “intends,” “targets,” “projects,”
“contemplates,” “believes,” “estimates,” “predicts,” “potential” or
“continue” or the negative of these terms or other similar expressions.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by the
forward-looking statements. We believe that these factors include, but
are not limited to, (i) the initiation, timing, progress and results of
our preclinical studies and clinical trials, and our research and
development programs; (ii) our ability to advance product candidates
into, and successfully complete, clinical trials; (iii) our reliance on
the success of our product candidates; (iv) the timing or likelihood of
regulatory filings and approvals; (v) our ability to expand our sales
and marketing capabilities; (vi) the commercialization of our product
candidates, if approved; (vii) the pricing and reimbursement of our
product candidates, if approved; (viii) the implementation of our
business model, strategic plans for our business, product candidates and
technology; (ix) the scope of protection we are able to establish and
maintain for intellectual property rights covering our product
candidates and technology; (x) our ability to operate our business
without infringing the intellectual property rights and proprietary
technology of third parties; (xi) costs associated with defending
intellectual property infringement, product liability and other claims;
(xii) regulatory developments in the United States, Europe and other
jurisdictions; (xiii) estimates of our expenses, future revenues,
capital requirements and our needs for additional financing; (xiv) the
potential benefits of strategic collaboration agreements and our ability
to enter into strategic arrangements; (xv) our ability to maintain and
establish collaborations or obtain additional grant funding; (xvi) the
rate and degree of market acceptance of our product candidates; (xvii)
developments relating to our competitors and our industry, including
competing therapies; (xviii) our ability to effectively manage our
anticipated growth; (xix) our ability to attract and retain qualified
employees and key personnel; (xx) our ability to achieve cost savings
and other benefits from our efforts to streamline our operations and to
not harm our business with such efforts; and (xxi) the use of proceeds
from our recent private placement. More detailed information about
Kadmon and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings with
the U.S. Securities and Exchange Commission (SEC), including the
Company’s Quarterly Report on Form 10-Q filed pursuant to Section 13 of
the Securities Exchange Act of 1934, as amended, with the SEC on May 15,
2017. Investors and security holders are urged to read these documents
free of charge on the SEC’s web site at www.sec.gov.
The Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future events
or otherwise.


Kadmon Holdings, Inc.
Ellen Tremaine, 646-490-2989
Conneighton, 212-600-1902